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Aims Mortality of maintenance haemodialysis (HD) patients is very high due to polymorbidity, mostly from metabolic and
cardiovascular disease. In order to identify patients with high risk for life-threatening complications, reliable prognos-
tic markers would be helpful. Pregnancy-associated plasma protein-A (PAPP-A) has been shown to predict cardio-
vascular events and death in patients with stable coronary artery disease as well as in acute coronary syndrome in
patients with normal renal function. It was the aim of this study to evaluate PAPP-A as a marker for death in patients
on maintenance HD.
Methods
and results
PAPP-A serum levels were measured in 170 patients participating in the monitor! trial, a prospective dynamic dialysis
cohort multicenter study in Switzerland. Patients were followed up for a median time of 17 months after measuring
PAPP-A, and evaluated for death of any cause. Survivors and non-survivors were compared with regard to baseline
PAPP-A concentrations. A multivariate logistic regression analysis for death was performed including PAPP-A, age,
sex, number of comorbidities, dialysis vintage, Kt/V, IL-6, C-reactive protein, parathyroid hormone (PTH),
Ca  PO4 product, and total serum cholesterol. A cut-off value for PAPP-A was calculated for discrimination
between patients with low and high mortality risk, respectively. A total of 23 deaths occurred during follow-up, equal-
ling an incidence rate of 0.1. Baseline median PAPP-A levels were 40% higher in non-survivors vs. survivors
(P ¼ 0.023). In a multivariate analysis, only PAPP-A, age, and Ca  PO4 product were independent predictors of mor-
tality. A cut-off value of 24 mIU/L discriminates significantly (P ¼ 0.015) between patients at low or high risk for death
with a negative predictive value of 91%.
Conclusion PAPP-A is a novel and independent short-time predictor of mortality in a maintenance HD population. The patho-
genetic relevance of PAPP-A, particularly in the development of cardiovascular disease, remains to be further
elucidated.
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Introduction
Haemodialysis (HD) treatment is associated with a high morbidity
and mortality, mainly due to cardiovascular complications.1
It would be desirable to have simple screening tools available
to assess an individual patient’s risk with regard to the occurrence
of medical complications including death. Pregnancy-
associated plasma protein-A (PAPP-A) is a high-molecular-weight,
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zinc-binding matrix metalloproteinase belonging to the metzincin
superfamily of metalloproteinases2 and was originally identified in
the plasma of pregnant women.3 It is widely used to exclude
foetal trisomy in the first trimester of gestation. PAPP-A was
also found to be abundantly expressed in eroded and ruptured vas-
cular plaques, but is only minimally expressed in stable plaques.4 In
addition, PAPP-A has been identified as an independent predictor
of cardiovascular events and death in patients with stable coronary
artery disease as well as in acute coronary syndrome (ACS).5 –7
Only limited data are available on PAPP-A in patients with
chronic renal failure and dialysis. PAPP-A levels are elevated in
chronic HD patients and transiently increase during HD sessions.8,9
The aim of this study was to assess the prognostic value of PAPP-A
as a predictor of mortality in patients on maintenance HD, and to
compare it to other prognostic risk markers and parameters of HD
quality.
Methods
Patient population and study design
The study population consists of 170 prevalent maintenance HD
patients participating in the monitor! trial, a prospective dynamic multi-
centre HD cohort study, including participants from seven hospital-
based dialysis units in Switzerland. All patients who had undergone
HD treatment for more than 3 months and who gave their written
informed consent were included into the study. The only exclusion cri-
terion was a predictable short-term drop-out, such as terminal illness
or planned change of renal replacement modality. The study protocol
has been approved by the institutional review boards of the respective
centres, and all participants gave written informed consent. A baseline
assessment including measurement of PAPP-A was performed at time
of inclusion into the monitor! cohort. The cohort was established
between autumn of 2006 and summer of 2007. In the present analysis,
all patients with a baseline PAPP-A measurement available (98% of the
cohort) are included.
Methods
All blood samples were drawn prior to start of dialysis sessions. Elec-
trolytes, creatinine, urea, cholesterol levels, and parathyroid hormone
(PTH) were measured locally in each dialysis centre. Blood samples for
interleukin-6 (IL-6) and PAPP-A from all participating sites were ana-
lysed in a central laboratory (University Hospital Zurich). Samples
for PAPP-A measurements were centrifuged and kept frozen at
2208C until analysis. PAPP-A concentration was measured immuno-
metrically by TRACE (Time Resolved Amplified Cryptate Emission)
on a Kryptorw analyser from Brahms AG Hennigsdorf, Germany,
with a coefficient of variation of 0.036. The assay is based on two
monoclonal antibodies that recognize the complexed heterotetra-
meric PAPP-A/proMBP (proform of eosinophil major basic protein),
originally developed to measure PAPP-A in pregnancy. To determine
whether PAPP-A concentrations are affected by HD, its levels were
measured in nine patients prior to and after a 4 h HD session.
Endpoints
The primary objective of this analysis was to examine the predictive
value of serum PAPP-A concentrations for all-cause mortality in main-
tenance HD patients. In addition, PAPP-A was to be assessed for pre-
diction of cardiovascular mortality and morbidity as secondary
outcomes. The following events were labelled as cardiovascular:
unstable angina, myocardial infarction, stroke, or arterial revasculariza-
tion procedures (PTCA, peripheral angioplasty of native vessels, and
arterio-venous fistulas). Medical charts of all participants were
reviewed in April 2008 by one investigator (Y.S.) for the occurrence
of medical complications, interventions, hospitalizations, and death.
As no patient prematurely terminated HD treatment, all deaths occur-
ring in the study population during reported follow-up were accounted
for. All events were analysed regarding their relation to cardiovascular
causes and to time of follow-up within the study cohort. A comorbid-
ity score adapted according to Davies et al.10 was used to characterize
patients with regard to possible confounding factors for mortality.
Statistics
Because of skewed distribution of most parameters examined, descrip-
tive statistics are given in terms of medians (interquartile range, IQR;
range), counts, and percentages, respectively. Differences between sur-
vivors and non-survivors were investigated by Mann–Whitney U test
in continuous variables and Fisher’s exact test in categorical variables.
Bivariate correlation analysis was performed according to Spearman
(Spearman’s rho). Multivariate logistic regression (method: enter)
was used to predict death as a dependent variable with PAPP-A as
an independent variable, and age, sex, number of comorbidities, time
on HD, C-reactive protein, IL-6, PTH, calcium  phosphate product
(Ca  PO4), and total serum cholesterol as covariates. A cut-off
value (C) for PAPP-A was calculated according to Jacobson and
Truax11 regarding the best sensitivity and specificity for prediction of
mortality: C ¼ (SD0  M1 þ SD1  M0)/(SD0 þ SD1), whereas M0
and SD0 ¼ mean and standard deviation of PAPP-A for patients
alive, M1 and SD1 ¼ mean and SD of PAPP-A for patients who died
during the study. A Kaplan–Meier survival analysis was calculated stra-
tified to PAPP-A cut-off value. The C-statistic for PAPP-A is reported
as a measure of its discriminative power. All statistical tests are two-
sided and P  0.05 was considered to be significant. All analyses
were carried out with SPSS for Windows, release 16.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Pregnancy-associated plasma protein-A measurements were avail-
able from 170 of 174 patients of the overall monitor! study cohort
(98%). Patient characteristics are shown in Table 1. Among the
total of 170 patients, 59 were women (35%), the median age
was 70 years, and median treatment time on HD was
71 months. During the 17.5 months median follow-up time,
23 patients died (13.5%), equivalent to an incidence rate of 0.1
per patient-year. In addition, four cardiovascular events not result-
ing in death occurred. Non-survivors were significantly older and
had slightly more comorbidities than survivors. In contrast, no
differences in sex, dialysis vintage, dialysis efficacy (measured as
Kt/V), and follow-up time were detectable between groups. Simi-
larly, survivors and non-survivors were statistically comparable
with regard to classical risk markers, such as C-reactive protein
and IL-6, as well as with regard to parameters of disturbances in
mineral metabolism, such as PTH and Ca  PO4 product. In con-
trast, baseline serum PAPP-A concentration was 40% higher
in non-survivors (P ¼ 0.008 for difference vs. ‘survivors’).
In a bivariate analysis, PAPP-A was related to dialysis vintage (r ¼
0.213, P ¼ 0.006), serum PTH (r ¼ 0.153, P ¼ 0.046), and
number of hospitalizations (r ¼ 0.165, P ¼ 0.031). In contrast, no
PAPP-A: a short-time predictor of mortality in patients on HD 355
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Patient characteristics according to survival status
Variable (normal range) All patients Survivorsa Non-Survivorsa P-value
Median (IQR)a Range Median (IQR) Median (IQR)
n 170 — 147 23 —
Sex (male/female), n 111/59 — 97/50 14/9 0.643b
Age, year 70 (57–77) 28–89 68 (55–76) 77 (72–80) 0.011
Follow-up, days 526 (463–553) 35–589 525 (463–553) 526 (498–553) 0.541
Time on HD, days 853 (403–1571) 34–4759 831 (393–1560) 995 (596–1978) 0.557
Comorbidities, n 1 (1–2) 0–5 1 (1–2) 2 (1–3) 0.444
PAPP-A, mIU/L 21 (15–26) 7–117 20 (15–25) 28 (19–35) 0.008
IL-6, ng/L 5.7 (2.9–11.2) 2–93 5.4 (2.9–10.7) 7.6 (3.8–17.3) 0.279
C-reactive protein, mg/L 4 (2–9) 0–79 5 (2–9) 3 (2-10) 0.563
Cholesterol, mmol/L 4.2 (3.7–4.8) 1.9–7.6 4.2 (3.7–4.8) 4.2 (3.3–4.8) 0.981
PTH, ng/L 210 (126–330) 6–1493 214 (132–331) 173 (95–296) 0.798
Ca  PO4, mmol2/L2 3.7 (3.1–4.4) 0.9–7.7 3.7 (3.1–4.3) 3.9 (2.5–5.0) 0.278
Kt/V 1.6 (1.40–1.75) 1–3 1.6 (1.40–1.80) 1.5 (1.30–1.70) 0.819
No. of CV endpoints, n 5 — 4 1 —
No. of death, n 24 — 0 23 —
aInterquartile range: 25th and 75th percentiles.
bFisher’s exact test.
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correlation was found with age, number of comorbidities, IL-6,
CRP, Ca  PO4 product, cholesterol or Kt/V (data not shown).
A multivariate logistic regression analysis for death was per-
formed with 159 patients (94% of the observed cohort, represent-
ing 21 deaths) of which complete data were available for the
computed variables. The model includes PAPP-A, age, sex,
number of comorbidities, dialysis vintage, IL-6, C-reactive
protein, PTH, Ca  PO4 product, and total serum cholesterol.
Of these variables, only PAPP-A, age, and Ca  PO4 product
were independent predictors for death from any cause (Table 2).
For IL-6, only a trend towards a correlation between elevated
serum levels and mortality was observed. All other variables did
not show a significant odds ratio in the model predicting
outcome. Also, PAPP-A remained significant if Kt/V was included
as additional parameter into the model (P ¼ 0.01, 95% CI
1.014–1.111; n ¼ 110 patients, 17 deaths), suggesting that its
levels are not merely reflective of dialysis quality.
Owing to the lack of reference ranges as risk score of mortality,
we calculated a cut-off value for PAPP-A regarding the best sensi-
tivity and specificity for prediction of mortality (Table 3) according
to Jacobsen and Truax.11 A cut-off value of 24 mIU/L discriminated
significantly (P ¼ 0.015) between patients at low or high risk for
death. In the low-risk group (PAPP-A ,24 mIU/L), 10 deaths
occurred among 112 patients (9%), in comparison to 13 deaths
among 58 patients (22%) in the high-risk group (PAPP-A
24 mIU/L). This translated into a sensitivity of 57%, a specificity
of 69%, a positive predictive value of 22%, and a negative predictive
value of 91% for the chosen cut-off of 24 mIU/L. When PAPP-A
was computed as dichotomous variable with the cut-off value of
24 mIU/L, an odds ratio of 3.2 for death resulted (P ¼ 0.04, 95%
CI 1.056–9.577); the C-statistic amounts to 0.67 (P ¼ 0.007,
95% CI 0.53–0.83), which indicates a sufficient discriminative
power. A Kaplan–Meier survival analysis of patients stratified
into two groups according to their PAPP-A cut-off value below
or above 24 mIU/L, respectively, is shown in Figure 1.
To determine alterations of PAPP-A levels during dialysis, its
levels were measured in nine patients each prior to and after a
4 h HD session. Average serum concentrations before and after
HD were 29.8+9 and 28.1+8, respectively (P ¼ 0.389).
Discussion
In this Swiss cohort of maintenance HD patients, PAPP-A was
identified as an independent short-time predictor of mortality.
Patients with a PAPP-A level of 24 mIU/L had an odds ratio of
3.2 to die within 1.5 years of follow-up compared with patients
with lower PAPP-A values. In contrast, patients with a PAPP-A
level of ,24 mIU/L had a likelihood of 91% to be alive at the
end of the observation period. To our best knowledge, this is
the first study having assessed PAPP-A as a prognostic factor in
maintenance HD patients.
Whether PAPP-A is merely a risk marker or causally involved in
the pathogenesis of cardiovascular and non-CV disorders leading
do death remains open for debate. Only a limited number of clini-
cal studies are available to resolve this issue. So far, PAPP-A was
found to be elevated in patients with coronary artery disease,5– 7
suggesting its potential relevance in the development of cardiovas-
cular pathology. In a non-dialysis population with ACS and an
average PAPP-A concentration of 14.2 mIU/L, PAPP-A levels
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Table 2 Multivariate logistic regression model (n 5
170)
Odds ratio 95% CI P-value
PAPP-A, mIU/L 1.048 1.009–1.088 0.015
Age, year 1.077 1.015–1.142 0.014
Sex, female 1.449 0.491–4.280 0.502
Comorbidities, n 1.339 0.797–2.252 0.270
Time on HD, days 1.000 0.999–1.000 0.655
IL-6, ng/L 1.049 0.991–1.111 0.101
CRP, mg/L 0.999 0.932–1.070 0.967
PTH, ng/L 1.000 0.998–1.002 0.694
Ca  PO4, mmol2/L2 1.692 1.009–2.837 0.046
Cholesterol, mmol/L 1.282 0.719–2.285 0.399
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 PAPP-A cut-off and respective number of
patients dead below/above cut-off
Total Dead
No risk (PAPP-A ,24 mIU/L); n (%) 112 (66) 10 (9)
At risk (PAPP-A 24 mIU/L); n (%) 58 (34) 13 (22)
Figure 1 Kaplan–Meier survival curve. The graph illustrates
cumulative survival for patients divided up by baseline PAPP-A
serum concentrations of either ,24 or 24 mIU/L (‘low’ and
‘high’ risk for mortality, respectively). P denotes the statistical sig-
nificance for the difference between groups with regard to the
univariate effect of PAPP-A on survival.
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above 12.6 mIU/L were associated with a significantly increased
odds ratio of 2.44 for death or non-fatal myocardial infarction
within 6 months of follow-up.6 In our own cohort, mean
PAPP-A concentrations were clearly higher with 21.9 mIU/L
(median 21 mIU/L), suggesting limited renal clearance of the
protein in chronic renal failure, and/or increased production due
to HD treatment or systemic vascular damage. Endogenous clear-
ance by the kidney may be negligible due to the size and structure
of the protein. With regard to the effect of renal replacement
therapy, in a group of patients undergoing chronic maintenance
HD or haemodiafiltration (HDF), mean pre-treatment PAPP-A
levels were reported to be 24.3 mIU/L, and to transiently increase
during HDF before returning to baseline levels after a 4 h session.9
In addition, our own measurements during HD revealed no rel-
evant changes in PAPP-A levels. Thus, it seems unlikely that
PAPP-A concentrations are substantially affected by dialysis treat-
ment or haemodialytic clearance. Similarly, PAPP-A is not merely
a marker of dialysis efficacy, as no correlation was found with
Kt/V in our own series. In conclusion, elevated serum PAPP-A con-
centrations in our study cohort most probably reflect systemic vas-
culopathy, which is a well-established complication leading to
cardiovascular morbidity and mortality in patients with chronic
renal failure.
Pregnancy-associated plasma protein-A is the protease for
insulin-like growth factor binding protein-4 (IGFBP-4), therefore
responsible for degradation of IGFBP-4, a potent inhibitor of
IGF-1 action. PAPP-A is reported to be secreted by activated
macrophages in the atherosclerotic plaque. IGF-1 stimulates cell
proliferation and differentiation, hence has been considered to
be a mediator of plaque growth. However, recent evidence
suggests that IGF-1 rather provides protection against ischaemic
vascular disease, with reduced IGF-1 levels being associated with
carotid and coronary artery disease. Protective action of IGF-1
includes preservation of insulin sensitivity and endothelial and
microvascular function. Therefore, increased PAPP-A levels may
actually offer protection by enhancing IGF-1 bioavailability as
part of a reparative pathway reactive to local vascular
damage.2,12,13 Further research on PAPP-A, especially in the
setting of chronic renal failure, will have to be undertaken to
better understand its exact role(s) in vascular pathobiology.
Several potential limitations apply to our study. First, the 24
deaths within our study cohort equates to a death rate of only
12 per 100 patient-years, which is somewhat lower than expected
in an HD population with a median age of 70 years (mean 66
years).14,15 This could reflect a healthy population or progress in
medical care. Most likely, it was the result of excluding patients
with limited lifetime expectancy. Given the rather small number
of deaths the amount of controlled variables in the multivariate
statistical model may be somewhat excessive. Therefore, the
results in logistic regression analyses should be interpreted care-
fully. Whatever the reason for the low mortality may be, the clini-
cal relevance of elevated PAPP-A concentrations thus becomes
even more important, as it helps to identify patients who are
otherwise less likely to experience death. Similarly, the median
observation time limited to 17 months can be seen as a disadvan-
tage, or, in contrast, as particularly helpful in predicting short-time
mortality. End-stage renal disease by itself constitutes a
cardiovascular risk factor contributing to the mortality exceeding
that of non-dialysis populations with coronary artery syndrome.
This may explain the shorter time to death in our study cohort
compared with that observed in other patients with elevated
PAPP-A levels not being on renal replacement therapy.7
However, with regard to other aspects, our cohort is quite com-
parable with other published series, and therefore makes our find-
ings applicable to a general maintenance HD population. The effect
of age on outcome is evident and has been shown, as well as for
the Ca  PO4 product, in other studies.16,17 In addition, and in
accordance with the concept of ‘reverse epidemiology’, classical
(cardiovascular) risk factors in patients without end-stage renal
disease, such as serum cholesterol, were not associated with
higher morbidity in the present analysis.18 Somewhat surprising,
classical markers of chronic inflammation were not predictive of
outcome in our cohort.19 Whereas for IL-6 a trend towards cor-
relation with mortality was found, C-reactive protein was clearly
unrelated to prognosis. Again, this may be indicative of a popu-
lation with a relatively low cardiovascular risk profile. Indeed, the
number of (confirmed) cardiovascular events in our study was
rather low. Because of this, we refrained from subgroup analyses
with stratification by aetiology. Moreover, the primary endpoint
of our study was ‘mortality from any cause’. With the reason for
death not being identifiable in most instances, it was presumed
‘cardiovascular’ in nature in the absence of other obvious causes.
In conclusion, we have identified PAPP-A as novel and indepen-
dent short-term predictor of mortality in maintenance HD
patients. It may be particularly useful in a population of patients
with low–to-intermediate cardiovascular risk. Owing to its poten-
tial to identify patients with imminent risk for death, repetitive
measurements in annual intervals may be advisable with regard
to tailoring an individual’s diagnostic and medical management.
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